Share this article on:

Effects of Exercise during Adjuvant Chemotherapy on Breast Cancer Outcomes

COURNEYA, KERRY S.1; SEGAL, ROANNE J.2; MCKENZIE, DONALD C.3; DONG, HUIRU1; GELMON, KAREN3,4; FRIEDENREICH, CHRISTINE M.5; YASUI, YUTAKA1; REID, ROBERT D.6; CRAWFORD, JENNIFER J.1; MACKEY, JOHN R.1,7

Medicine & Science in Sports & Exercise: September 2014 - Volume 46 - Issue 9 - p 1744–1751
doi: 10.1249/MSS.0000000000000297
Epidemiology

Observational studies suggest that physical activity after a breast cancer diagnosis is associated with improved cancer outcomes; however, no randomized data are available. Here, we report an exploratory follow-up of cancer outcomes from the Supervised Trial of Aerobic versus Resistance Training (START).

Methods: The START was a Canadian multicenter trial that randomized 242 breast cancer patients between 2003 and 2005 to usual care (n = 82), supervised aerobic (n = 78), or resistance (n = 82) exercise during chemotherapy. The primary end point for this exploratory analysis was disease-free survival (DFS). Secondary end points were overall survival, distant DFS, and recurrence-free interval. The two exercise arms were combined for analysis (n = 160), and selected subgroups were explored.

Results: After a median follow-up of 89 months, there were 25/160 (15.6%) DFS events in the exercise groups and 18/82 (22.0%) in the control group. Eight-year DFS was 82.7% for the exercise groups compared with 75.6% for the control group (HR, 0.68; 95% confidence interval (CI), 0.37–1.24; log-rank, P = 0.21). Slightly stronger effects were observed for overall survival (HR, 0.60; 95% CI, 0.27–1.33; log-rank, P = 0.21), distant DFS (HR, 0.62; 95% CI, 0.32–1.19; log-rank, P = 0.15), and recurrence-free interval (HR, 0.58; 95% CI, 0.30–1.11; Gray test, P = 0.095). Subgroup analyses suggested potentially stronger exercise effects on DFS for women who were overweight/obese (HR, 0.59; 95% CI, 0.27–1.27), had stage II/III cancer (HR, 0.61; 95% CI, 0.31–1.20), estrogen receptor-positive tumors (HR, 0.58; 95% CI, 0.26–1.29), human epidermal growth factor receptor 2-positive tumors (HR, 0.21; 95% CI, 0.04–1.02), received taxane-based chemotherapies (HR, 0.46; 95% CI, 0.19–1.15), and ≥85% of their planned chemotherapy (HR, 0.50; 95% CI, 0.25–1.01).

Conclusions: This exploratory follow-up of the START provides the first randomized data to suggest that adding exercise to standard chemotherapy may improve breast cancer outcomes. A definitive phase III trial is warranted.

1Faculty of Physical Education, University of Alberta, Edmonton, Alberta, CANADA; 2Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, CANADA; 3School of Kinesiology, University of British Columbia, Vancouver, British Columbia, CANADA; 4British Columbia Cancer Agency, Vancouver, British Columbia, CANADA; 5Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Alberta, CANADA; 6University of Ottawa Heart Institute, Ottawa, Ontario, CANADA; and 7Cross Cancer Institute, Edmonton, Alberta, CANADA

Address for correspondence: Kerry S. Courneya, Ph.D., E-488 Van Vliet Center, Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada, T6G 2H9; E-mail: kerry.courneya@ualberta.ca.

Submitted for publication December 2013.

Accepted for publication January 2014.

© 2014 American College of Sports Medicine